Trial Profile
A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms ARCADE
- Sponsors Amgen
- 17 Jun 2018 Results (n=146) presented at the 23rd Congress of the European Haematology Association.
- 12 Dec 2017 Pooled safety results of NCT00095264 and NCT01362140 (n=352) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 18 Nov 2017 Planned number of patients changed from 141 to 180.